A PHASE III, MULTI¿CENTER, RANDOMIZED, DOUBLE¿MASKED, SHAM¿CONTROLLED STUDY TO INVESTIGATE THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF RO7200220 ADMINISTERED INTRAVITREALLY IN PATIENTS WITH UVEITIC MACULAR EDEMA
- Registry ID
- GR44277
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Sponsor
- HOFFMANN-LA ROCHE LIMITED
- Start date
- 2023-05-31
- Last update
- 2022-12-21
Conditions
Related clinical trials
- AN EIGHTEEN-MONTH, TWO-ARM, RANDOMIZED, DOUBLE-MASKED, MULTICENTER, PHASE III STUDY ASSESSING THE EFFICACY AND SAFETY OF BROLUCIZUMAB VERSUS AFLIBERCEPT IN ADULT PATIENTS WITH VISUAL IMPAIRMENT DUE TO MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION (RAVEN)
- AN EIGHTEEN-MONTH, TWO-ARM, RANDOMIZED, DOUBLE-MASKED, MULTI-CENTER, PHASE III STUDY ASSESSING THE EFFICACY AND SAFETY OF BROLUCIZUMAB VERSUS AFLIBERCEPT IN ADULT PATIENTS WITH VISUAL IMPAIRMENT DUE TO MACULAR EDEMA SECONDARY TO BRANCH RETINAL VEIN OCCLUSION (RAPTOR)
- TREATMENT FOR CENTRAL-INVOLVED DIABETIC MACULAR EDEMA IN EYES WITH VERY GOOD VISUAL ACUITY
- A 12-MONTH, RANDOMIZED, DOUBLE-MASKED, SHAM-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF 0.5MG RANIBIZUMAB INTRAVITREAL INJECTIONS IN PATIENTS WITH VISUAL IMPAIRMENT DUE TO VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) DRIVEN MACULAR EDEMA (ME).
View on source registry